论文部分内容阅读
目的探讨槐耳颗粒联合全身化疗对晚期乳腺癌患者免疫功能及预后的影响。方法将我院2006年3月至2009年3月期间收治的晚期(Ⅳ期)乳腺癌患者98例按均衡随机化方法随机分为研究组和对照组,对照组仅行单纯全身化疗,研究组给予槐耳颗粒联合全身化疗,槐耳颗粒于化疗开始第1 d同时应用,分别于化疗前1 d及研究实施6个月时检测2组患者外周血T淋巴细胞亚群及IL-2水平,同时观察2组患者3年死亡率和中位生存期。结果化疗前1 d,研究组与对照组CD_4~+、CD_8~+、CD_4~+/CD_8~+T淋巴细胞及IL-2水平比较差异均无统计学意义(P>0.05)。研究实施6个月时,研究组CD_4~+、CD_4~+/CD_8~+T淋巴细胞及IL-2水平明显高于对照组〔CD_4~+:(47.35±6.23)%比(41.33±5.61)%,P<0.05;CD_4~+/CD_8~+:1.84±0.42比1.47±0.33,P<0.05;IL-2水平:(1.78±0.45)μg/L比(1.58±0.30)μg/L,P<0.05〕,CD_8~+T淋巴细胞明显低于对照组〔(23.26±3.25)%比(29.77±4.12)%,P<0.05〕。研究组化疗并发症发生率及3年内死亡率明显低于对照组〔并发症发生率:58.3%(28/48)比86.0%(43/50),P<0.01;3年内死亡率:62.5%(30/48)比82.0%(41/50),P<0.05〕。研究组中位生存期明显长于对照组(33.5个月比24.5个月,P<0.01)。结论从本研究结果初步得出,槐耳颗粒联合全身化疗可以明显提高晚期乳腺癌患者的免疫功能,降低化疗副反应,并改善患者的预后,为中西医结合治疗肿瘤进行有益的探索。
Objective To investigate the effects of Huaier granules combined with systemic chemotherapy on immune function and prognosis of patients with advanced breast cancer. Methods A total of 98 patients with advanced stage (Ⅳ) breast cancer who were treated in our hospital from March 2006 to March 2009 were randomly divided into study group and control group according to the method of equilibrium randomization. The control group received simple systemic chemotherapy. The combination of Huaier particles and systemic chemotherapy, Huaier particles in the first day of chemotherapy at the same time the application, respectively, 1 d before chemotherapy and 6 months of study to test the two groups of patients with peripheral blood T lymphocyte subsets and IL-2 levels, At the same time, the 3-year mortality and median survival of 2 groups were observed. Results There was no significant difference in the levels of CD_4 ~ +, CD_8 ~ +, CD_4 ~ + / CD_8 ~ + T lymphocytes and IL-2 between study group and control group on day 1 before chemotherapy (P> 0.05). The levels of CD_4 ~ +, CD_4 ~ + / CD_8 ~ + T lymphocytes and IL-2 in the study group were significantly higher than those in the control group at the 6th month of study [CD4 +: (47.35 ± 6.23)% vs (41.33 ± 5.61) (P <0.05). The level of IL-2 in serum was (1.78 ± 0.45) μg / L (1.58 ± 0.30) μg / L, P <0.05]. CD_8 ~ + T lymphocytes were significantly lower than those in the control group [(23.26 ± 3.25)% vs (29.77 ± 4.12)%, P <0.05〕. The incidence of chemotherapy complications and the 3-year mortality in the study group were significantly lower than those in the control group (complication rate: 58.3% (28/48) vs 86.0% (43/50), P <0.01; 3-year mortality rate: 62.5% (30/48) vs 82.0% (41/50), P <0.05〕. The median survival time was significantly longer in the study group than in the control group (33.5 months versus 24.5 months, P <0.01). Conclusions From the results of this study, it was initially concluded that the combination of Huaier particles and systemic chemotherapy can significantly improve the immune function of patients with advanced breast cancer, reduce the side effects of chemotherapy, and improve the prognosis of patients for the treatment of tumor Integrative Medicine useful exploration.